Madopar

Levodopa/Benserazide, the active ingredient in Madopar, is a dopamine precursor / dopa decarboxylase inhibitor combination presented as a tablet for oral use. It treats Parkinson's disease and Parkinsonian syndromes in adults.

GNH USA supplies Madopar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is an oral ant Parkinsonian agent that acts on the dopaminergic pathway to improve motor function.

- Parkinson's disease: reduces tremor, rigidity, bradykinesia and improves overall motor performance. - Parkinsonian syndrome: alleviates motor symptoms caused by secondary Parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief when levodopa alone is insufficient.

Madopar may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or arrhythmia - Neuroleptic malignant syndrome - Severe allergic reactions (rash, angioedema) - Sudden onset of mood swings or depression

When prescribing Madopar, clinicians should consider several safety measures.

- Dose titration: increase dose gradually under medical supervision to minimise side effects. - Renal impairment: monitor kidney function and adjust dosing if needed. - Cardiovascular disease: use caution due to risk of orthostatic hypotension. - Psychiatric history: monitor for hallucinations, confusion or mood changes. - Concomitant MAO‑B inhibitors: avoid unless specifically directed by a physician. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Madopar interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may trigger hypertensive crisis. - Antipsychotics (e.g., haloperidol): can diminish levodopa efficacy. - Strong antihypertensive agents: may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: can increase levodopa plasma levels. - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: may compete with levodopa transport across the gut, affecting absorption.